0:03:06

Jeffrey Skolnik, MD on INO-5401 in Combination with PD-1 Inhibitor Libtayo @InovioPharma

Cancer-News

1 month

12 Views

Share Report Add to 0 0

Share Video (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://www.oncologytube.com/videoEmbed/38955/jeffrey-skolnik-md-on-ino-5401-in-combination-with-pd-1-inhibitor-libtayo-inoviopharma?channelName=Cancer-News" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Share Video (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://www.oncologytube.com/videoEmbed/38955/jeffrey-skolnik-md-on-ino-5401-in-combination-with-pd-1-inhibitor-libtayo-inoviopharma?channelName=Cancer-News"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://www.oncologytube.com/videoEmbed/38955/jeffrey-skolnik-md-on-ino-5401-in-combination-with-pd-1-inhibitor-libtayo-inoviopharma?channelName=Cancer-News" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Other

Description:

Jeffrey Skolnik, MD of INOVIO Pharmaceuticals @InovioPharma discusses INO-5401 in combination with PD-1 inhibitor libtayo (cemiplimab) demonstrates 85% of newly diagnosed glioblastoma patients are alive 12 months following treatment.

Read here: http://s23.q4cdn.com/479936946/files/doc_news/INOVIOs-INO-5401-in-Combination-with-PD-1-Inhibitor-Libtayo-cemiplimab-Demonstrates-85-of-Newly-Diagnosed-Glioblastoma-Patients-Are-A-5VT78.pdf